



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/735,273	12/11/2000	Edwin A. Clark	WIBL-P01-534	3583
28120	7590	06/16/2005	EXAMINER	
FISH & NEAVE IP GROUP ROPES & GRAY LLP ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			SWITZER, JULIET CAROLINE	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 06/16/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/735,273

Applicant(s)

CLARK ET AL.

Examiner

Juliet C. Switzer

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 24 March 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 12, 14, 17, 19, 29 and 36-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 12, 14, 17, 19, 29 and 36-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 3/24/05.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

1. This action is written in response to applicant's correspondence submitted 3/24/05. Claims 12, 14, 17, 19, 29, and 36-41 are pending. Claims 12, 14, 36, and 38, Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections not reiterated in this action have been withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
2. Consonant with the previous species election (see paper filed 10/22/02) for claims which recite more than one gene the elected species fibronectin has been examined.
3. The IDS filed 3/24/05 has been considered. The signed 1449 is enclosed with this office action.

### ***Claim Rejections - 35 USC § 112***

4. Claims 12, 14, 17, 19, 29, and 36-41 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The rejection is maintained over the pending claims. The rejection has been modified to clarify the examiner's grounds for rejection.

### **Nature of the invention**

The claims are drawn to methods of predicting the likelihood of development of a metastatic condition via the determination of the level of a gene product which alters the actin-based cytoskeleton of one or more tumor cells, comparison to a control wherein the level relative

Art Unit: 1634

to the control is determinative of the increased likelihood of developing a metastatic condition. Some claims require only that the biological sample be a “biological sample from a human” and some require that the sample be tumor cells. In some cases the control is a non-metastatic control and a “greater” level of expression is an indicator of increased likelihood, while others recite that the control is a metastatic control and an increased likelihood is indicated if there is equal expression in the sample and the control. Thus, the nature of the invention is within the field of biotechnology, and depends on the knowledge of a correlation between levels of gene products which alter the actin-based cytoskeleton of tumor cells and likelihood of development of metastatic disorder.

#### **Breadth of the claims**

Claim 12 is drawn to a method of predicting the likelihood of development of a metastatic condition in a human, comprising the steps of (a) determining the level of one or more gene products, excluding RhoC and Hsp70, which alter the actin-based cytoskeleton of one or more tumor cells in a human in a biological sample from a human; and (b) comparing the level determined in (a) with a non-metastatic control, wherein if the level determined in (a) is greater than the level of the gene product in the non-metastatic control, then the mammal has an increased likelihood of developing a metastatic condition.

Thus, claim 12 encompasses the detection of the level of any possible gene product that alters the “actin-based cytoskeleton” of any tumor cell. The number of products encompassed within this recitation is enormous and includes hundreds and potentially thousands of products which are both discovered and yet to be discovered. The claim encompasses the use of any biological sample whether or not the sample contains tumor cells. The claim encompasses

Art Unit: 1634

determining a predisposition to any possible metastatic condition, including those associated with any type of cancer. The claim encompasses the determination of “gene product” which is construed as encompassing assaying for both polypeptide and mRNA. Claim 17 depends from claim 12 and recites a number of possible metastatic conditions, specifically listing metastatic forms of thirteen different cancers and “combinations thereof.” Claim 19 depends from claim 12 and recites that the biological sample is a blood sample or a cell sample from a tumor.

Claim 14 differs from claim 12 in that it recites a number of possible gene products, with fibronectin being the species of this listing elected for prosecution. This claim has only been considered in this rejection insofar as it recites fibronectin. Further, claim 14 is limited to determining the level of the gene product in tumor cells. Like claim 12, claim 14 is sufficiently broad so as to include the prediction of an increased likelihood of the development of ANY metastatic condition based on the observance of an increased level of fibronectin gene product, wherein gene product encompasses at least detecting expressed protein or mRNA. Claim 29 is similar in scope to the elected species of claim 14 but differs in that it only recites that the gene product is fibronectin, while claim 14 recites a Markush group that is limited by election.

Claims 36-41 differ from the preceding claims in that the control is a metastatic control, comparing step (b) states wherein if the level determined in (a) is the same as the level of the gene product in the metastatic control, then the mammal has an increased likelihood of developing a metastatic condition.

As noted, the claims read on predicting the likelihood of development of any possible metastatic condition, with some of the claims being narrowed in that they recite a laundry list of possible conditions, “or combinations thereof.” The claims do not recite the nature of the

Art Unit: 1634

likelihood of development, how this increased or decreased likelihood is to be measured, or what constitutes a clinically or statistically significant change in the likelihood of developing a metastatic condition compared to a control. Some of the claims encompass making predictions based on any tissue sample, and at any point in a human's life. For example, claim 12, as written encompasses the prediction that a healthy patient will develop a metastatic condition at any point in their lifetime, based on, for example, a blood sample.

Further, many of the claims read on determining the level of any gene product or combination of gene products that alter the actin cytoskeleton. The claims do not specifically recite the nature of the alteration of the cytoskeleton, or the manner in which the gene product induces this alteration. Any change in cell shape or size requires an alteration of the cytoskeleton, as does movement of the cell, secretion of products by the cell, endocytosis, pinocytosis, exocytosis, cell division, apoptosis, and many types of transportation of substances from location to location within the cell. There is an large number of gene products which have the potential to either directly or indirectly affect any of these processes, and thereby alter the cytoskeleton.

### **Direction and Guidance**

The specification teaches the injection of two different melanoma cell lines (one mouse cell line (B16) and one human cell line (A375)) into mice (page 25). From metastatic lesions in these mice, cell lines were developed which were identified as having increased metastatic potential relative to the parental cell lines. Differential display was carried out on these cell lines, and a number of differentially expressed genes were identified (Table 1, p. 19). Three genes, fibronectin, rhoC, and thymosin  $\beta$ 4 were identified as being expressed at higher levels in

Art Unit: 1634

all three metastases selected from both human and mouse samples (p. 30). The specification teaches numerous assays for proliferation, chemotaxis, and metastatic potential of the cell lines (page 28).

Absent from the specification is any guidance as to how the results observed in the differential expression analysis of metastatic melanoma cell lines would be extrapolated to any and all potential types of metastatic conditions. Further, absent from the specification is any guidance as to how one could use a blood sample for the prediction of metastatic potential, as all of the observations in the instant specification are based on tumor cell lines. Absent from the specification is any guidance as to how much difference in “gene product” must be observed in order to conclude that an increased likelihood of development of metastatic condition is present. Further, absent from the specification is any follow-up validation of the differential expression assay, an absence which is critical in view of the unpredictable state of the prior art.

#### **State of the Prior Art / Level of Predictability in the Art**

The prior art teaches numerous gene products that alter the actin-based cytoskeleton of one or more tumor that demonstrate an altered level of expression in metastatic tissue. However, it is highly unpredictable within the class of all “actin-based cytoskeleton” altering gene products which would be useful as predictors of metastatic conditions in melanoma or in any other cancer. Suwa, et al., British Journal of Cancer 77(1):147-153, 1998 (hereinafter “Suwa”), for example, teaches a statistically significant correlation between expression of the rhoC gene in pancreatic ductal adenocarcinoma and metastasis. However, Suwa also teaches that no such correlation exists between metastasis and expression of genes closely related to rhoC such as rhoA or rhoB (Suwa, abstract). RhoA and rhoB are also gene products which alter the actin-based

Art Unit: 1634

cytoskeleton. Indeed, applicant's own specification affirms such a discrepancy for the melanoma cell lines tested herein, teaching at page 9 that RhoA is expressed at equivalent levels in both poorly and highly metastatic tumors.

The prior art demonstrates a high level of unpredictability with regard to the relationship between gene product levels and cancer metastasis. For example, Kawanishi *et al.* (Cancer, April 15, 1999, Vol. 85, No 8, p. 1649) teach that the frequency of lymph node metastases was higher in tumors that were negative for HSP70 gene products in patients with squamous cell carcinoma of the esophagus (p. 1653). On the other hand, Kaur *et al.* (Oral Oncology 34(1998) 496-501) observed that oral cancer patients with elevated levels of HSP70 showed decreased disease free survival rate associated with increased HSP70 gene product, wherein disease free survival includes lack of recurrence or metastasis (p. 499, first column). These papers illustrate that the utilization of gene products as indicators of future prognosis is a highly unpredictable situation. In a third study, Volm *et al.* (Clin. Exp. Metastasis, 1996, 14, 209-214) were unable to establish any relationship between the expression of HSP70 and the occurrence of metastases in primary ovarian carcinomas. Though the scope of these claims specifically excludes HSP70, these studies illustrate the fact that for a given gene product different research groups have made different research observations concerning the relationship between gene products and metastases.

As another example, Yamamoto *et al.* (Biochemical and Biophysical Research Communications, Vol. 193, No. 2, 1993, p. 706-710) found that the mRNA gene product of the thymosin  $\beta$ -4 gene was present at higher levels in tumors without metastasis than in non-tumorous mucosa, and that this transcript was overexpressed in non-metastatic cells versus



Art Unit: 1634

metastatic cells. Again, this observation is the opposite of the observation for this same gene in the instant specification. It is highly unpredictable as to which result is more reliable, or why the results differ. For example, do the results differ because the instant examples are concerning melanoma cells and cell lines while Yamamoto *et al.* examined colorectal tumors and cell lines? Do the results differ because the instant examples utilized tumors from a mouse model and Yamamoto *et al.* examined tumors from human tissue? Is there some other reason the results differ, and in fact are opposite of one another? The specification provides no guidance for making this determination, and the consideration of the prior art only highlights the high degree of unpredictability in this invention.

Levedakou *et al.* (Internation Journal of Cancer: 52, 534-537 (1992)) found that Matrix Gla protein was over-expressed in tumor tissues compared to matched normal tissues for renal-cell carcinoma and testicular germ-cell carcinomas. They also found that there for these patients there was an inverse correlation between the level of MGP expression and lymph-node metastasis- that is the LOWER level of MGP was associated with the increased level of metastasis. Again, this observation is opposite that of the instant specification (p. 535). In this case, Levedakou *et al.* were using DNA probes and Northern analysis to determine expression levels (p. 534).

With regard to claims which recite the measurement of fibronectin (FN) gene product as an indicator of metastatic potential, the prior art repeatedly teaches that the presence or increase of fibronectin expression and/or gene products in tumors is significantly associated with LOW metastatic potential (exactly the opposite result as implied by the instant amended and added claims). For example, Christensen *et al.* (Cancer Research, 48, 6227-6233, 1988) measured FN

Art Unit: 1634

gene product via staining of the FN protein itself in invasive breast carcinoma and found that while 87% of patients without evidence of metastatic spread had FN positive tumors, only 33% of women with metastatic spread had FN positive tumors (ABSTRACT and throughout). When they tested the metastatic lesions themselves, Christensen *et al.* found that the local recurrences tended to display the same staining pattern, whereas axillary lymph node metastases showed inconsistent staining patterns (p. 6228, paragraph bridging columns). Linlang *et al.* (Journal of Medical Colleges of PLA (1996), 11(3)224-226) teach that decrease or disappearance of FN in basement membrane plays a crucial role in tumor metastasis (p. 226). Xu *et al.* (Baiquien Yike Dixue Xuebao (1998) 24(4), 368-369, English abstract provided for applicant's convenience) teach that in the serum of non metastasis patients FN expression was more than double that of the expression in the blood of patients with metastasis lesions, and that the FN expression in the metastasized laryngeal tumor was faint or disappeared. Takei *et al.* (International Journal of Oncology, 12, 517-523, 1998) did not observe an association between FN expression and lymph node metastases or tumor size in invasive breast carcinoma. These references highlight the extreme unpredictability associated with using an increased fibronectin expression observation in a tumor cell as an indicator of metastatic potential, since it has been shown that decreased FN expression in primary tumor is an indicator of increased metastatic potential, when there was an observable correlation. The instant specification shows only that FN expression is increased in metastatic lesions wherein these lesions originated from melanoma cell lines injected into mice. Cell lines may not be an accurate predictor of actual tumor progression, as these have been thorough multiple passages and crises and have been being kept under artificial conditions. Thus, at best cell lines are a poorer representation of malignancy than the actual tumors

Art Unit: 1634

examined in the prior art references cited herein because they have survived crisis and have adapted an immortal life in culture, and thus has been enabled to survive in its artificial environment.

It is unpredictable whether the discrepancies observed within the prior art and between the data in the prior art and the instant examples are differences in methodology, or differences between different types of cancer, or differences in the activity of gene products at different points in cancer progression, etc. There is no predictable way to determine which possible factor is the most meaningful in attempting to apply the data of the specification or the data in the prior art.

#### **Existence of Working Examples**

The specification demonstrates that some genes are differentially expressed in metastatic lesions of cell lines injected into mice, and that in particular fibronectin is over expressed in more highly metastatic cells. With regard to human cancers, only cells which originated from a single human cancer melanoma cell line were examined. The specification does not provide a single working example of the claimed invention, that is an example where increased gene product was used as an indicator of metastatic potential. The specification does not test blood samples or primary tumor samples, or metastatic lesions that arise from actual primary tumor cells (as opposed to injected cell lines). The specification teaches the use of multiple cell lines of known metastatic potential injected into nude mice (page 25). The specification further teaches the creation of several sublines of A375 cells which over express rhoC, rhoA or GFP (page 28). The specification teaches numerous assays for proliferation, chemotaxis, and metastatic potential of the cell lines (page 28). The specification does not

Art Unit: 1634

provide working examples of the assay of non-tumor tissue, or even non-metastatic tissue, as having observable differential levels of gene products, all methods which are encompassed within the claimed invention.

### **Quantity of Experimentation Required**

An enormous amount of experimentation would be required in order to practice the claimed invention for the prediction of an increased likelihood of developing melanoma metastases, let alone for the practice of the claimed invention for the prediction of an increased likelihood of predicting any possible metastatic condition in any human, healthy or already presenting with cancer. The experimentation would require the screening of hundreds of potential markers within which alter the actin-based cytoskeleton in any number of possible cancerous conditions in large patient cohorts order to attempt to establish any validated correlation between the presence of gene product at higher levels than non-metastatic tissue and an increased likelihood of developing metastatic conditions. The claims are drawn to the prediction of the likelihood of the development of a metastatic condition in a human based on an increased level of expression of a gene that alter the actin cytoskeleton, some claims particularly reciting fibronectin as the gene. In order to make and use the invention, one of skill in the art would be required to determine a particular metastatic condition and human for further study. The skilled artisan would then be required to collect biological samples from normal individuals and those suspected of developing a metastatic condition. The level of expression of hundreds of genes would have to be determined, in triplicate to insure accurate results, from all tissue samples. The skilled artisan would then be required to wait, perhaps several years, to evaluate

Art Unit: 1634

the progression of the metastatic conditions in the tested mammals using some form of objective and quantitative measuring system.

### **Conclusion**

In view of the breadth of the claims, in view of the limited guidance provided by the specification, in view of the unpredictability of the art, in view of the level of experimentation required, the specification does not describe the claimed invention in such a way as to enable one of skill in the art to make and/or use the invention.

### ***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 12, 14, 17, 19, 36, 37, 38, and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by Friedman *et al.* (Cancer Epidemiology, Biomarkers & Prevention, Vol. 4, pages 549-554, July/August 1995).

With regard to claim 12, Friedman *et al.* teach a method comprising the steps of:

(a) determining the level of one gene product which alters the actin-based cytoskeleton of one or more tumor cells in a human in a biological sample from a human, the gene product being TGF $\beta$ 1; and (b) comparing the level determined in (a) with a non-metastatic control (p. 549-550; Table 1). Friedman *et al.* further teach that the level of TGF $\beta$ 1 gene product observed in a biological sample is greater in cancers that progressed to metastasis (metastatic cancers) than when compared to ca(non-metastatic) (p. 498).

Art Unit: 1634

With regard to claim 14, Friedman *et al.* teaches the gene product is TGF $\beta$ 1, which is a member of the TGF $\beta$  superfamily. It is noted that TGF $\beta$ 1 is not the elected species, but for this claim no art was located related to the elected species, and so a non-elected species was selected for further consideration.

With regard to claim 17, Friedman *et al.* teach that the metastatic sites include the liver, lungs and bone (p. 551).

With regard to claim 19, the sample is a cell sample (tumor cells within tumor tissues).

With regard to claim 36, Friedman *et al.* teach a method comprising the steps of (a) determining the level of one gene product which alters the actin-based cytoskeleton of one or more tumor cells in a human in a biological sample from a human, the gene product being TGF $\beta$ 1; and (b) comparing the level determined in (a) with a metastatic control (p. 550-551). Ka Friedman *et al.* compare the results of the testing of a number metastatic lesions with one another, and thus meet the limitation of step (b). K Friedman *et al.* further teach that the level of TGF $\beta$ 1 gene product observed in a the biological sample (tumor tissue from a node positive tissue) is the same as those other metastatic controls in that these have “elevated” levels of TGF $\beta$ 1 (p. 550).

With regard to claim 37, the sample is a cell sample (tumor cells within tumor tissues).

With regard to claim 38, Friedman *et al.* teaches the gene product is TGF $\beta$ 1, which is a member of the TGF $\beta$  superfamily. It is noted that TGF $\beta$ 1 is not the elected species, but this claim is included in the rejection because it does recite TGF $\beta$ 1.

With regard to claim 39, the sample is a cell sample (tumor cells within tumor tissues).

Thus, the method taught by Friedman *et al.* appears to meet all of the structural limitations of the instant claims.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 36, 37, 38, 39, 40, 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Christensen *et al.* (Cancer Research 1988).

With regard to claims 36 and 40, Christensen *et al.* teach a method comprising the steps of (a) determining the level of one gene product which alters the actin-based cytoskeleton of one or more tumor cells in a human in a biological sample from a human, the gene product being Fibronectin; and (b) comparing the level determined in (a) with a metastatic control (p. 6227).

Art Unit: 1634

Christensen *et al.* compare the results of the testing of metastatic lesions with one another, and thus meet the limitation of step (b). Christensen *et al.* further teach that the level of FN gene product observed in a the biological sample (tumor tissue from a node positive tissue) is the same as those other metastatic controls in that all of these have “lower” levels of FN than non-metastatic samples and teach that FN staining reaction is an excellent prognostic factor of metastatic potential (p. 6232).

With regard to claim 37, the sample is a cell sample (tumor cells within tumor tissues).

With regard to claim 38, Christensen *et al.* teaches the gene product is fibronectin.

With regard to claims 39 and 40, the sample is a cell sample (tumor cells within tumor tissues).

The teachings of Christensen *et al.* do not anticipate the instant claims because the biological samples used by Christensen *et al.* are taken from autopsies, and thus, there is no need to predict if the human has an increased likelihood of developing a metastatic condition. However, in view of the teachings of Christensen *et al.*, it would have been prima facie obvious to have applied the methodologies taught by Christensen *et al.* to the prediction of an increased likelihood of development of a metastatic condition in a human as Christensen *et al.* specifically teach that FN levels are an excellent prognostic factor for metastatic potential. Therefore, in view of the teachings of Christensen *et al.* the instant claims are prima facie obvious.

### **Response to Remarks**

The remarks are addressed as they are presented in turn beginning on page 6 of the response.



Art Unit: 1634

The 112 1<sup>st</sup> paragraph lack of enablement rejection is maintained and modified to address the amendments to the claims.

Applicant's state at page 7 of the remarks that "the instant application also teaches skilled artisans the specific gene products and how to validate the specific gene products..." referring specifically to an example concerning RhoC. It is noteworthy that RhoC has been specifically excluded from the scope of the claims. Nonetheless, this argument is not persuasive. The fact that the potential markers have not been validated is an extremely large omission considering the high level of unpredictability in this endeavor, especially noting that for genes within the broad class of genes encompassed by applicant's claims the prior art provides teachings that directly conflict with applicant's results. Furthermore, it is noted that the scope of many of the claims is much broader than even the genes which are specifically discussed in the specification, and even includes genes which the specification exemplifies are not overexpressed in cells with high metastatic potential. There is no means for predicting which genes that "alter the actin-based cytoskeleton" will actually function in this assay and which will not. This lack of predictability and lack of guidance is especially troublesome since the specification and the prior art demonstrate that at least some genes within this class (RhoA and RhoB) would not be useful for these methods.

Applicant's provide arguments to support the murine model for studying metastasis models (p. 7, final ¶). The examiner does not doubt the utility of the model, however applicant's claims suggest that the data observed in their study is an endpoint for drawing conclusions based on the ability to used the differentially expressed genes as markers for predicting an increased likelihood of developing any and all metastatic disease at any point in a human's life using any

Art Unit: 1634

tissue sample from the human. Indeed, turning to the abstract by Anderson, this grant abstract discusses a number of steps which would be carried out after differential analysis of tissues from the mouse model, and Anderson suggests that even after these steps she will have only provided “a significant advance in the search for... better diagnostic markers of metastasis.” With regard to the comment by Margalit et al., such a statement was only made years after the study by Clark et al. and cannot be considered to enable the claimed invention because it is unknown what further validation occurred between the writing of Margalit et al. and the original paper. At the time the invention was made, as provided in the instant specification, there was not validation of a single potential prognostic marker within the scope of the instant claims.

Applicant states that the examiner is concerned that the specification teaches only results obtained with tumor cell lines. To the contrary, the rejection discusses all of the examples in the specification, including that which is summarized in the first full paragraph on page 8 of the remarks (see portions of the rejection discussing direction and guidance and examples). It is highly unpredictable how these findings can be applied in the instant methods due to the fact that they are not validated findings, and the state of the art as a whole coupled with the findings in the instant specification suggest that there is an high degree of unpredictability regarding the presence of gene products of genes which alter the actin based cytoskeleton in general, and fibronectin in particular, and metastatic potential. As noted in the rejection, the specification does not test blood samples or primary tumor samples, or metastatic lesions that arise from actual primary tumor cells (as opposed to injected cell lines). The specification further teaches the creation of several sublines of A375 cells which over express rhoC, rhoA or GFP (page 28). The specification teaches numerous assays for proliferation, chemotaxis, and metastatic potential of

Art Unit: 1634

the cell lines (page 28). The specification does not provide working examples of the assay of non-tumor tissue, or even non-metastatic tissue, as having observable differential levels of gene products, all methods which are encompassed within the claimed invention.

Applicants note that the findings that support the instant invention have been published in Nature (final full ¶ page 8). This is irrelevant when considering the question of lack of enablement. The determination by Nature that the findings were scientifically relevant does not support applicant's claims that the findings are sufficient to establish a reliable predictive relationship for (1) all gene products that alter the actin based cytoskeleton or (2) the elected embodiment of fibronectin in particular. The discussion by Ridley mentioned by applicant does in fact discuss the interesting aspects of Applicant's work, but does not conclude, as applicant's have, that this work is sufficient for the provision of a prognostic test for the development of any possible metastatic disease in a human based on the testing of any possible gene that affects the actin based cytoskeleton (or even any of the particularly recited genes in the instant claims) or fibronectin in particular, at any point in a human's life based on a sample of any possible tissue or even a sample from blood or tumor tissue. Instead, Ridley concludes by saying that "The challenge will be to extend this work from a mouse model of metastasis to human patients." Thus, to Ridley it is not a foregone conclusion that this work will extend to human patients, but instead, Ridley says that this extension will be "a challenge."

Finally, applicant cites papers which were filed subsequent to the filing of this application in support of the instant invention. In each of these cases significant and unpredictable work was undertaken to validate targets suggested by applicant in their specification. These do not address the scope of the claims, nor do they address the lack of guidance in the specification as to which

Art Unit: 1634

genes of those listed will be reliable prognostic markers. For example, thought Goldstein et al. were able to confirm what applicant suggested, this does not remove the fact that at the time of filing, there was a conflicting suggestion regarding this same gene product in the prior art (see discussion of Yamamoto et al. in the rejection). Furthermore, since each of these references was published after the filing of the instant application, these references do not support applicant's arguments that the specification was sufficient to enable the claimed invention at the time of filing since MPEP 2124 states,

“...it is impermissible to use a later factual reference to determine whether the application is enabled or described as required under 35 U.S.C. 112, first paragraph. In re Koller, 613 F.2d 819, 823 n. 5, 204 USPQ 702, 706 n.5 (CCPA 1980). References which do not qualify as prior art because they postdate the claimed invention may be relied upon to show the level of ordinary skill in the art at or around the time the invention was made. Ex parte Erlich, 22 USPQ 1463 (Bd. Pat. App. & Inter. 1992).”

The premise of applicant's invention is the fact that certain genes were observed to be over expressed in metastatic lesions versus primary tumors in a mouse model using mRNA array analysis. However, applicant has not established that this over expression would be observed anywhere but in the metastatic melanoma lesions that arose from injected melanoma cell lines. That is, applicant has not established that a similar pattern of expression would be observed in a primary tumor that may become metastatic or in the blood of a healthy patient that might develop a metastatic disease or even in the blood of a patient with cancer that may or may not develop a metastatic condition. It is not at issue here whether one could perform differential expression assays, it is at issue whether these assays would be predictive in the ways that applicant's claims suggest. Quite simply, the specification has not provide ample evidence to support these claims, in light of the high level of unpredictability in this art, as is highlighted in the case of fibronectin.

Art Unit: 1634

The examiner is not requiring knowledge of any exact mechanism of action, but instead evidence of a clear association with predictive value, as is needed to practice the claimed invention.

Therefore, having carefully considered each of applicant's arguments, the rejection is  
MAINTAINED.

The rejection of claims 12, 14, 19, 36, 37, 38, and 39 under 35 U.S.C. 102(b) as being anticipated by Kaur *et al.* is WITHDRAWN in view of applicant's amendment which exclude HSP70 from the scope of the claims.

The rejection in view of Christensen *et al.* is maintained. Applicant points to the 112 1<sup>st</sup> paragraph as stating that the state of the art before the filing of the present application is such that the expression level of fibronectin gene was not found to consistently correlate with the potential to develop a metastatic condition. However, reviewing the references cited in the rejection, it is found that in all but one the researchers found that decreased FN expression occurred in association with metastasis, as taught by Christensen *et al.* This is relevant to the 112 1<sup>st</sup> question in this application because applicant is teaching the opposite of what was established in the prior art. Applicants also discuss the teachings of Christensen *et al.* in an article in APMIS Supplementum (1992). Quoting from page 14 applicant points out that Christensen *et al.* teach that *in vivo* findings have been more inconsistent depending on methods used to prepare and fix tissues. However, in this same section Christensen *et al.* further teach that even in view of these potential inconsistencies the differential expression of FN has been observed in metastatic lymph nodes. Further, it does not appear that Christensen *et al.* are suggesting that FN expression cannot be detected in tumor cells, merely that one should select methodologies that have given more consistent results. At page 9 of their discussion, Christensen *et al.* definitively state that

Art Unit: 1634

“Metastatic carcinoma cells from human breast and rat prostate gland have been found to produce a significantly reduced amount of FN as compared to non-metastasizing carcinoma cells from the same organ (p. 11, 2<sup>nd</sup> column).” Christensen et al. further state that “There is no doubt, however, that the presence of FN within breast cancer tissues as demonstrated by immunohistochemistry reflects important changes in IBC development and metastasis.” As noted by applicant, Christensen et al. do state that the significance of FN for the prognosis of breast cancer has not been definitively established, but they further teach that though not definitive “The presence of a universal, intense FN immunoreactivity within the stroma appears to reflect a low metastatic potential of the tumor” and “FN... may also have a protective effect on tumor invasiveness and metastasis.” Thus, though not definitive, all of the evidence presented by Christensen et al. supports the use of decreased FN as an indicator of an increased likelihood of metastatic disease. Applicant’s point out that Christensen et al. teach away from the methods of claims 14 and 29. Christensen et al. has not been applied to these claims. For the claims that were rejected, however, this rejection is MAINTAINED.

### *Conclusion*

9. No claims are allowed.

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1634

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet C Switzer whose telephone number is (571) 272-0753. The examiner can normally be reached on Monday through Wednesday, from 9:00 AM until 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached by calling (571) 272-0745.

The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-0507.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of

Art Unit: 1634

the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

A handwritten signature in black ink, reading "Juliet C. Switzer". The signature is fluid and cursive, with a long horizontal flourish extending to the right.

Juliet C. Switzer  
Primary Examiner  
Art Unit 1634

June 10, 2005